NCT04169386View on ClinicalTrials.gov

A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 23, 2018

Primary Completion Date

November 22, 2018

Study Completion Date

November 22, 2018

Conditions
Hypercholesterolaemia
Interventions
DRUG

AK102

AK102 single dose administered subcutaneously

DRUG

Placebo

Placebo single dose administered subcutaneously

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
collaborator

AD Pharmaceuticals Co., Ltd.

INDUSTRY

lead

Akeso

INDUSTRY

NCT04169386 - A Study of PCSK9 Inhibitor AK102 in Healthy Subjects | Biotech Hunter | Biotech Hunter